Glenmark’s Goa Facility Receives U.S. FDA Inspection Report with VAI Status

Glenmark Pharmaceuticals has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) following an inspection of its formulations manufacturing facility in Goa.

The U.S. FDA inspected the facility between 22 June and 30 June 2026. The inspection has now been classified as Voluntary Action Indicated (VAI), according to the company’s regulatory disclosure.

An EIR is issued by the FDA after an inspection has been completed. A VAI classification indicates that the regulator has identified objectionable conditions but is not recommending regulatory action at that stage. The company is expected to address the identified issues through appropriate voluntary corrective measures.

Glenmark’s Goa facility is part of its manufacturing network and produces pharmaceutical formulations for its global operations. The company has manufacturing facilities across several countries and supplies medicines to markets around the world.

The latest regulatory update provides the formal outcome of the June inspection. However, Glenmark’s exchange filing did not disclose detailed information about the individual observations made during the inspection or the specific corrective measures associated with them.

For pharmaceutical manufacturers supplying regulated markets such as the United States, FDA inspections are an important part of ongoing GMP oversight. Manufacturing sites are assessed to determine whether their processes, facilities and quality systems meet applicable regulatory expectations.

Glenmark’s latest disclosure therefore marks the conclusion of the FDA inspection process at its Goa formulations facility, with the site receiving a VAI classification following the June 2026 inspection.

23-09-2026